Nitric oxide in multikinase inhibitor-induced hand-foot skin reaction-Reference-Cited by-同舟云学术

Nitric oxide in multikinase inhibitor-induced hand-foot skin reaction

Published:2022-07 Issue: Volume:245 Page:82-98
ISSN:1931-5244
Container-title:Translational Research
language:en
Short-container-title:Translational Research

Author:

CHEN LEYING^ORCID,WU ZHAOYU,YANG LINAN,CHEN YUYUN,WANG WENHONG,CHENG LITING,LI CHONG,LV DAZHAO,XIA LIANGYONG,CHEN JIA,TANG LINA,ZHANG LI,ZHANG SHIYI,LUO JIE^ORCID

Publisher

Elsevier BV

Subject

Biochemistry (medical),Public Health, Environmental and Occupational Health,General Medicine,Physiology (medical)

Reference40 articles.

1. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: update of a multicenter phase II trial;Thompson;J Clin Oncol,2006

2. Multikinase inhibitor-induced hand–foot skin reaction: a review of clinical presentation, pathogenesis, and management;Chanprapaph;Am J Clin Dermatol,2016

3. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib;Lipworth;Oncology,2009

4. Evolving strategies for the management of hand–foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib;Lacouture;Oncologist,2008

5. Search for evidence-based approaches for the prevention and palliation of hand–foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs);Anderson;Oncologist,2009

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma;Expert Opinion on Drug Metabolism & Toxicology;2024-09-03

2. Pleiotropic effects of nitric oxide sustained-release system for peripheral nerve repair;Acta Biomaterialia;2024-07

3. Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study;Journal of Gastrointestinal Oncology;2024-06